Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.05 Analyst target: $40.00 Upside: 1851.22%
Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.